Cytokine regulation networks in the cancer microenvironment.
暂无分享,去创建一个
Su-Cheng Huang | Bor-Ching Sheu | B. Sheu | Ho-Hsiung Lin | Ho-Hsiung Lin | D. Chang | Wen-Chun Chang | Chieh-Yang Cheng | Daw-Yuan Chang | Chieh-Yang Cheng | W. Chang | Su‐cheng Huang
[1] R. Bonavia,et al. Stromal Cell-derived Factor 1α Stimulates Human Glioblastoma Cell Growth through the Activation of Both Extracellular Signal-regulated Kinases 1/2 and Akt , 2003 .
[2] L. Wakefield,et al. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. , 2003, The Journal of clinical investigation.
[3] C. Roussos,et al. Tumor Necrosis Factor-α Promotes Malignant Pleural Effusion , 2007 .
[4] Cheng Dong,et al. Targeting Mutant V600EB‐Raf in Melanoma Interrupts Immunoediting of Leukocyte Functions and Melanoma Extravasation , 2007, Cancer research.
[5] A. Lindén,et al. Interleukin-17 family members and inflammation. , 2004, Immunity.
[6] B. Sheu,et al. A novel role of metalloproteinase in cancer-mediated immunosuppression. , 2001, Cancer research.
[7] Y. Ben-Neriah,et al. NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.
[8] H. Weiner,et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells , 2006, Nature.
[9] J. Chirgwin,et al. The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. , 2007, Cancer letters.
[10] G. Trinchieri,et al. Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.
[11] Penny A. Johnson,et al. Mechanisms of local immunosuppression in cutaneous melanoma , 2007, British Journal of Cancer.
[12] B. Sheu,et al. Predominant Th2/Tc2 Polarity of Tumor-Infiltrating Lymphocytes in Human Cervical Cancer1 , 2001, The Journal of Immunology.
[13] H. Nakshatri,et al. NF-κ B Promotes Breast Cancer Cell Migration and Metastasis by Inducing the Expression of the Chemokine Receptor CXCR4* , 2003, Journal of Biological Chemistry.
[14] T. Malek,et al. Tolerance, not immunity, crucially depends on IL-2 , 2004, Nature Reviews Immunology.
[15] P. Carmeliet,et al. Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer , 2004, Cancer Research.
[16] Y. Shyr,et al. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. , 2007, Cancer research.
[17] R. Schreiber,et al. A critical function for type I interferons in cancer immunoediting , 2005, Nature Immunology.
[18] M. Ratajczak,et al. Trafficking of Normal Stem Cells and Metastasis of Cancer Stem Cells Involve Similar Mechanisms: Pivotal Role of the SDF‐1–CXCR4 Axis , 2005, Stem cells.
[19] Wen‐Chun Chang,et al. Immune concept of human papillomaviruses and related antigens in local cancer milieu of human cervical neoplasia , 2007, The journal of obstetrics and gynaecology research.
[20] D. Jablons,et al. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. , 2005, American journal of respiratory cell and molecular biology.
[21] G. Watkins,et al. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer , 2005, Breast Cancer Research.
[22] T. Whiteside,et al. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. , 2006, Seminars in cancer biology.
[23] H. Moses,et al. Stromal fibroblasts in cancer initiation and progression , 2004, Nature.
[24] J. Carucci,et al. Human basal cell carcinoma is associated with Foxp3+ T cells in a Th2 dominant microenvironment. , 2007, The Journal of investigative dermatology.
[25] R. Lechler,et al. The maintenance of human CD4+ CD25+ regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. , 2007, International immunology.
[26] I. Fidler,et al. Regulation of neoplastic angiogenesis. , 2000, Journal of the National Cancer Institute. Monographs.
[27] T. Whiteside,et al. Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment , 2007, Cancer Immunology, Immunotherapy.
[28] S. Zheng,et al. IL-2 Is Essential for TGF-β to Convert Naive CD4+CD25− Cells to CD25+Foxp3+ Regulatory T Cells and for Expansion of These Cells1 , 2007, The Journal of Immunology.
[29] 石山 宏平. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans , 2006 .
[30] G. Bastert,et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis , 2000, Breast Cancer Research and Treatment.
[31] B. Sipos,et al. Tumor Stroma Interactions Induce Chemoresistance in Pancreatic Ductal Carcinoma Cells Involving Increased Secretion and Paracrine Effects of Nitric Oxide and Interleukin-1β , 2004, Cancer Research.
[32] S. Wahl,et al. TGF-β: the missing link in CD4+CD25+ regulatory T cell-mediated immunosuppression , 2003 .
[33] W. Wold,et al. Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAIL , 2008, Cancer Gene Therapy.
[34] M. Doucet,et al. TGF‐β Promotes the Establishment of Renal Cell Carcinoma Bone Metastasis , 2006 .
[35] P. L. Bergsagel,et al. Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.
[36] M. Lotze,et al. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. , 2004, Immunology letters.
[37] S. Steigen,et al. Reduced expression of microenvironmental Th1 cytokines accompanies adenomas–carcinomas sequence of colorectum , 2007, Cancer Immunology, Immunotherapy.
[38] S. Segal,et al. CD11b+/Gr-1+ Immature Myeloid Cells Mediate Suppression of T Cells in Mice Bearing Tumors of IL-1β-Secreting Cells1 , 2005, The Journal of Immunology.
[39] A. Chang,et al. Cutting Edge: Th17 and Regulatory T Cell Dynamics and the Regulation by IL-2 in the Tumor Microenvironment1 , 2007, The Journal of Immunology.
[40] K. Korach,et al. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. , 2003, Molecular endocrinology.
[41] E. Robertson,et al. IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. , 2008, Blood.
[42] Dafeng Yang,et al. Downregulation of IFN‐γR in association with loss of Fas function is linked to tumor progression , 2008, International journal of cancer.
[43] D. Longo,et al. Ammonium Trichloro(dioxoethylene-o,o′)tellurate (AS101) Sensitizes Tumors to Chemotherapy by Inhibiting the Tumor Interleukin 10 Autocrine Loop , 2004, Cancer Research.
[44] M. Detmar,et al. Effects of rIFN alpha, beta, and gamma on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro. , 1990, The Journal of investigative dermatology.
[45] M. Büchler,et al. On the TRAIL to therapeutic intervention in liver disease , 2007, Hepatology.
[46] Toshikazu Nakamura,et al. Hepatocyte growth factor and the Met system as a mediator of tumor–stromal interactions , 2006, International journal of cancer.
[47] D A Hilton,et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.
[48] A. Roberts,et al. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-α and TGF-β , 2005, Journal of Cell Science.
[49] T. Blankenstein. The role of tumor stroma in the interaction between tumor and immune system. , 2005, Current opinion in immunology.
[50] P. Allavena,et al. Increased Survival, Proliferation, and Migration in Metastatic Human Pancreatic Tumor Cells Expressing Functional CXCR4 , 2004, Cancer Research.
[51] M. Roncarolo,et al. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. , 2005, Blood.
[52] S. Chow,et al. Expression of inhibitory natural killer receptors on tumor‐infiltrating CD8+ T lymphocyte lineage in human endometrial carcinoma , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[53] Dennis C. Sgroi,et al. Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion , 2005, Cell.
[54] M. Berger,et al. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. , 2001, Cancer research.
[55] R. Greil,et al. Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. , 2000, Blood.
[56] L. Liotta,et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen , 1980, Nature.
[57] Xin-Yuan Fu,et al. Smad4 signalling in T cells is required for suppression of gastrointestinal cancer , 2006, Nature.
[58] Kathleen M. Smith,et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2–dependent mechanisms with implications for psoriasis pathogenesis , 2006, The Journal of experimental medicine.
[59] T. Horikoshi,et al. Inhibitory effect of human fibroblast interferon (HuIFN‐β) on the growth and invasive potential of cultured human melanoma cells in vitro , 1992, The British journal of dermatology.
[60] E. Mayhew,et al. Uveal melanoma expression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptors and susceptibility to TRAIL-induced apoptosis. , 2004, Investigative ophthalmology & visual science.
[61] C. Bucana,et al. Constitutive expression of interferon beta in differentiated epithelial cells exposed to environmental stimuli. , 1998, Cancer biotherapy & radiopharmaceuticals.
[62] S. Chien,et al. Tumor-derived factors impaired motility and immune functions of dendritic cells through derangement of biophysical characteristics and reorganization of cytoskeleton. , 2007, Cell motility and the cytoskeleton.
[63] R. Kastelein,et al. Swords into plowshares: IL-23 repurposes tumor immune surveillance. , 2007, Trends in immunology.
[64] C. Jobin,et al. STAT3 regulates NF-κB recruitment to the IL-12p40 promoter in dendritic cells , 2005 .
[65] C. Dinney,et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[66] T. Rème,et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma , 2007, Leukemia.
[67] T. Mcclanahan,et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation , 2005, The Journal of experimental medicine.
[68] S. Hayward,et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. , 2005, Oncogene.
[69] Y. Saga,et al. Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. , 2003, Cancer research.
[70] B. Nathwani,et al. IL-6 levels and genotype are associated with risk of young adult Hodgkin lymphoma. , 2004, Blood.
[71] C. Gregory,et al. Enhanced Apoptotic Cell Clearance Capacity and B Cell Survival Factor Production by IL-10-Activated Macrophages: Implications for Burkitt’s Lymphoma1 , 2005, The Journal of Immunology.
[72] M. Battaglia,et al. Tr1 cells: from discovery to their clinical application. , 2006, Seminars in immunology.
[73] B. Bonavida,et al. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[74] A. Mastro,et al. Metastatic breast cancer induces an osteoblast inflammatory response. , 2008, Experimental cell research.
[75] N. Munshi,et al. Multiple myeloma: A prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment , 2007, Journal of cellular biochemistry.
[76] W. Leonard,et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. , 2008, Blood.
[77] Y. Chang,et al. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. , 1999, Human immunology.
[78] Wan-Wan Lin,et al. A cytokine-mediated link between innate immunity, inflammation, and cancer. , 2007, The Journal of clinical investigation.
[79] Hiroshi Yasui,et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. , 2005, Blood.
[80] Cheng Dong,et al. Regulation of interleukin-8 expression in melanoma-stimulated neutrophil inflammatory response. , 2007, Experimental cell research.
[81] J. Votaw,et al. Silencing of CXCR4 blocks breast cancer metastasis. , 2005, Cancer research.
[82] Yuka Kanno,et al. Signaling by IL‐12 and IL‐23 and the immunoregulatory roles of STAT4 , 2004, Immunological reviews.
[83] R. Schreiber,et al. The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.
[84] J. Soulier,et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma , 2007, Leukemia.
[85] I. Holen,et al. Osteoprotegerin (OPG) Produced by Bone Marrow Stromal Cells Protects Breast Cancer Cells from TRAIL-Induced Apoptosis , 2004, Breast Cancer Research and Treatment.
[86] A. Wong,et al. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. , 2006, Endocrinology.
[87] R. Derynck,et al. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors , 1994, The Journal of cell biology.
[88] K. Liao,et al. Interactions of host IL-6 and IFN-γ and cancer-derived TGF-β1 on MHC molecule expression during tumor spontaneous regression , 2008, Cancer Immunology, Immunotherapy.
[89] D. Farkas,et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. , 2006, Cancer research.
[90] H. Murakami,et al. Th1/Th2 Cells in Patients with Multiple Myeloma , 2004, Hematology.
[91] N. Restifo,et al. Assumptions of the tumor 'escape' hypothesis. , 2002, Seminars in cancer biology.
[92] N. Munshi,et al. Focus on multiple myeloma. , 2004, Cancer cell.
[93] C. Bucana,et al. Modulation of the invasive phenotype of human colon carcinoma cells by organ specific fibroblasts of nude mice. , 1992, Differentiation; research in biological diversity.
[94] J. Massagué,et al. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. , 2003, Nature reviews. Cancer.
[95] Brian Barnett,et al. Bone Marrow Is a Reservoir for CD4+CD25+ Regulatory T Cells that Traffic through CXCL12/CXCR4 Signals , 2004, Cancer Research.
[96] B. Sipos,et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma , 2006, Oncogene.
[97] T. Wang,et al. Inflammation, atrophy, and gastric cancer. , 2007, The Journal of clinical investigation.
[98] A. Rudensky,et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells , 2005, Nature Immunology.
[99] L. Liotta,et al. Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells , 1990, The Journal of cell biology.
[100] M. Lotze,et al. Interleukin-17 promotes angiogenesis and tumor growth. , 2003, Blood.
[101] Brian Bierie,et al. Tumour microenvironment: TGFβ: the molecular Jekyll and Hyde of cancer , 2006, Nature Reviews Cancer.
[102] F. Marincola,et al. Interleukin‐10 and the immune response against cancer: a counterpoint , 2005, Journal of leukocyte biology.
[103] C. Bucana,et al. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells. , 1990, Journal of the National Cancer Institute.
[104] R. Bargou,et al. Signalling and survival pathways in multiple myeloma. , 2006, European journal of cancer.
[105] M. Lotze,et al. IL-17 Enhances the Net Angiogenic Activity and In Vivo Growth of Human Non-Small Cell Lung Cancer in SCID Mice through Promoting CXCR-2-Dependent Angiogenesis1 , 2005, The Journal of Immunology.
[106] Elise C. Kohn,et al. The microenvironment of the tumour–host interface , 2001, Nature.
[107] H. Moses,et al. Induction by transforming growth factor-β1 of epithelial to mesenchymal transition is a rare event in vitro , 2004, Breast Cancer Research.
[108] Kazuhiro Yoshida,et al. Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[109] Michael Karin,et al. IKK/NF-κB signaling: balancing life and death – a new approach to cancer therapy , 2005 .
[110] P. Comoglio,et al. The Met pathway: master switch and drug target in cancer progression , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[111] J. Ritz,et al. IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops , 1998, Oncogene.
[112] A. Verma,et al. Transforming Growth Factor-β Signaling in Normal and Malignant Hematopoiesis , 2007 .
[113] M. Karin. Nuclear factor-κB in cancer development and progression , 2006, Nature.
[114] D. W. Kim,et al. CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells. , 2003, The Journal of clinical endocrinology and metabolism.
[115] Geoffrey C Gurtner,et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.
[116] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[117] L. Coussens,et al. Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.
[118] S. Sakaguchi. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self , 2005, Nature Immunology.
[119] H. Alexander,et al. Journal of Translational Medicine Interleukin-1 and Cancer Progression: the Emerging Role of Interleukin-1 Receptor Antagonist as a Novel Therapeutic Agent in Cancer Treatment , 2022 .
[120] Luzhe Sun,et al. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. , 2007, Cancer research.
[121] B. Sheu,et al. Reversed CD4/CD8 ratios of tumor‐infiltrating lymphocytes are correlated with the progression of human cervical carcinoma , 1999, Cancer.
[122] Jack D Bui,et al. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? , 2007, Current opinion in immunology.
[123] K. Pienta,et al. Expression of CXCR4 and CXCL12 (SDF‐1) in human prostate cancers (PCa) in vivo , 2003, Journal of cellular biochemistry.
[124] S. Chow,et al. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma. , 2005, Cancer research.
[125] Yoichiro Iwakura,et al. Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. , 2007, Cancer research.
[126] M. Bar‐eli,et al. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[127] P. Gariglio,et al. Interleukin‐10 promotes B16‐melanoma growth by inhibition of macrophage functions and induction of tumour and vascular cell proliferation , 2002, Immunology.
[128] E. Mayhew,et al. Expression and possible function of IL-2 and IL-15 receptors on human uveal melanoma cells. , 2004, Investigative ophthalmology & visual science.
[129] Brian Bierie,et al. A delicate balance: TGF‐β and the tumor microenvironment , 2007, Journal of cellular biochemistry.
[130] M. Roncarolo,et al. Differentiation of Tr 1 cells by immature dendritic cells requires IL-10 but not CD 25 CD 4 Tr cells , 2005 .
[131] B. Sheu,et al. Current concepts of tumor-infiltrating lymphocytes in human malignancies. , 2005, Journal of reproductive immunology.
[132] Brian Bierie,et al. TGF-beta and cancer. , 2006, Cytokine & growth factor reviews.
[133] R. J. Kelleher,et al. Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells1 , 2007, The Journal of Immunology.
[134] S. Chow,et al. Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. , 2003, Cancer research.
[135] T. Hirano,et al. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. , 2002, Cytokine & growth factor reviews.
[136] T. Mcclanahan,et al. IL-23 promotes tumour incidence and growth , 2006, Nature.
[137] Lieve Moons,et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. , 2005, Cancer research.
[138] H. Moch,et al. Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.